The cellular transport of retinoic acid (RA) and 9-cis-RA is believed to be mediated by their cellular RA-binding protein, CRABP. The biological activity of these retinoids in the control of cellular differentiation and growth is mediated by their nuclear receptors, RARs (alpha, beta, and gamma) for RA and RXRs (alpha, beta, and gamma) for 9-cis-RA. The mechanism by which the nuclear receptors accept their ligands from the cytosol and are activated is not known, and forms the central theme of this proposal. The efficacy of RAs complexed with CRABP as compared with free RAs in the ligand-nuclear receptor interactions will be determined by using purified receptor protein preparations. The specific role of RA- response elements (REs) in enhancing/stabilizing the RA binding to the receptors, and the role of CRABP/RA in producing such effects will be elucidated by using a gel mobility shift assay. Also to be established will be, by the use of intact nuclei, the mode of transfer of RAs into the nuclei for their interactions with RAR/RXR. Experiments will be devised to utilize expression plasmids harboring full-length cDNA for CRABP, RAR and RXR to elucidate the specific role of CRABP in the binding of the ligands to the transiently expressed receptors in CV-1 cells. A CRABP- mediated functional role of RAR/RXR will be delineated by using a cis- trans cotransfection assay which would utilize cDNA expression vectors for the nuclear receptors and RARE/RXRE-chloramphenicol acetyl transferase. By extending these efforts, identification of possible activator/antagonist synthetic retinoids (from a rationally selected group of retinoids) that would alter the transcriptional activation of the receptors will also be accomplished. The unifying hypothesis to be tested is that CRABP plays a role not only in the transport of RAs to their nuclear receptors but that it also has a functional role.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA059446-02
Application #
2100045
Study Section
Metabolic Pathology Study Section (MEP)
Project Start
1994-08-07
Project End
1997-07-31
Budget Start
1995-08-01
Budget End
1996-07-31
Support Year
2
Fiscal Year
1995
Total Cost
Indirect Cost
Name
Southern Research Institute
Department
Type
DUNS #
006900526
City
Birmingham
State
AL
Country
United States
Zip Code
35205
Shealy, Y F; Hill, D L; Sani, B P et al. (1998) Anhydroretinol, a retinoid active in preventing mammary cancer induced in rats by N-methyl-N-nitrosourea. Oncol Rep 5:857-60
Muccio, D D; Brouillette, W J; Breitman, T R et al. (1998) Conformationally defined retinoic acid analogues. 4. Potential new agents for acute promyelocytic and juvenile myelomonocytic leukemias. J Med Chem 41:1679-87
Shealy, Y F; Frye, J L; Hill, D L et al. (1998) Retinyl substituted-benzyl ethers. Inhibition of mammary carcinogenesis by retinyl 3,4,5-trimethoxybenzyl ether (RTMBE). Anticancer Drug Des 13:159-82
Venepally, P; Reddy, L G; Sani, B P (1997) Analysis of homo- and heterodimerization of retinoid receptors in solution. Arch Biochem Biophys 343:234-42
Sani, B P; Venepally, P R; Levin, A A (1997) Didehydroretinoic acid: retinoid receptor-mediated transcriptional activation and binding properties. Biochem Pharmacol 53:1049-53
Shealy, Y F; Frye, J L; Riordan, J M et al. (1997) Retinyl ethers as cancer chemopreventive agents. Suppression of mammary cancer. Anticancer Drug Des 12:15-33
Venepally, P; Reddy, L G; Sani, B P (1996) Characterization of cellular retinoic acid-binding protein I from chick embryo and its ligand binding properties. Arch Biochem Biophys 336:231-9
Sani, B P; Zhang, X; Hill, D L et al. (1996) Retinyl methyl ether: binding to transport proteins and effect on transcriptional regulation. Biochem Biophys Res Commun 223:293-8
Venepally, P; Reddy, L G; Sani, B P (1996) Analysis of the effects of CRABP I expression on the RA-induced transcription mediated by retinoid receptors. Biochemistry 35:9974-82
Sani, B P; Venepally, P; Zhang, X K et al. (1996) Biochemical characteristics and differentiating activity of 4-oxo analogs of retinoic acid. Anticancer Res 16:1177-81

Showing the most recent 10 out of 11 publications